Cantor Fitzgerald Comments on NeuroPace FY2025 Earnings

NeuroPace, Inc. (NASDAQ:NPCE) – Equities research analysts at Cantor Fitzgerald issued their FY2025 earnings per share (EPS) estimates for shares of NeuroPace in a research note issued to investors on Tuesday, January 21st. Cantor Fitzgerald analyst R. Osborn anticipates that the company will post earnings of ($0.79) per share for the year. The consensus estimate for NeuroPace’s current full-year earnings is ($1.00) per share.

Other analysts also recently issued research reports about the company. JPMorgan Chase & Co. boosted their price objective on NeuroPace from $9.00 to $14.00 and gave the stock an “overweight” rating in a research note on Tuesday, December 17th. UBS Group began coverage on NeuroPace in a report on Tuesday. They issued a “buy” rating and a $17.00 target price on the stock. Finally, Wells Fargo & Company decreased their target price on NeuroPace from $15.00 to $13.00 and set an “overweight” rating on the stock in a report on Wednesday, November 13th. One research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $15.33.

NeuroPace Stock Up 7.5 %

NPCE opened at $14.04 on Thursday. NeuroPace has a one year low of $5.45 and a one year high of $18.15. The company has a debt-to-equity ratio of 6.03, a quick ratio of 4.77 and a current ratio of 5.59. The stock’s fifty day moving average is $11.13 and its 200-day moving average is $8.52. The company has a market capitalization of $419.07 million, a PE ratio of -14.04 and a beta of 2.02.

NeuroPace (NASDAQ:NPCE) last announced its earnings results on Tuesday, November 12th. The company reported ($0.19) earnings per share for the quarter, beating the consensus estimate of ($0.26) by $0.07. The firm had revenue of $21.06 million for the quarter, compared to the consensus estimate of $19.33 million. NeuroPace had a negative return on equity of 205.41% and a negative net margin of 36.74%. During the same quarter in the previous year, the business earned ($0.28) EPS.

Insider Activity

In other NeuroPace news, major shareholder Ltd. Kck sold 223,991 shares of the business’s stock in a transaction dated Friday, October 25th. The stock was sold at an average price of $5.45, for a total value of $1,220,750.95. Following the transaction, the insider now owns 5,270,845 shares in the company, valued at $28,726,105.25. The trade was a 4.08 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. 22.20% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. KCK LTD. acquired a new position in NeuroPace in the 4th quarter valued at approximately $58,981,000. Millennium Management LLC raised its holdings in NeuroPace by 13.3% in the 2nd quarter. Millennium Management LLC now owns 686,037 shares of the company’s stock valued at $5,186,000 after acquiring an additional 80,324 shares in the last quarter. Geode Capital Management LLC raised its holdings in NeuroPace by 8.7% in the 3rd quarter. Geode Capital Management LLC now owns 317,192 shares of the company’s stock valued at $2,211,000 after acquiring an additional 25,330 shares in the last quarter. State Street Corp grew its stake in shares of NeuroPace by 9.1% in the 3rd quarter. State Street Corp now owns 155,490 shares of the company’s stock valued at $1,084,000 after purchasing an additional 12,912 shares during the period. Finally, Bank of New York Mellon Corp bought a new stake in NeuroPace during the 2nd quarter worth approximately $257,000. Hedge funds and other institutional investors own 78.83% of the company’s stock.

About NeuroPace

NeuroPace, Inc operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely.